Risk Stratification Using the CHA$_2$DS$_2$-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

Guido Parodi, MD, PhD; Fernando Scudiero, MD; Rodolfo Citro, MD, PhD; Angelo Silverio, MD; Benedetta Bellandi, MD; Concetta Zito, MD, PhD; Francesco Antonini-Canterin, MD; Fausto Rigo, MD; Chiara Zocchi, MD; Eduardo Bossone, MD, PhD; Jorge Salerno-Uriarte, MD, PhD; Federico Piscione, MD, PhD; Carlo Di Mario, MD, PhD; on the behalf of Takotsubo Italian Network (TIN)*

Background—The CHA$_2$DS$_2$-VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA$_2$DS$_2$-VASc score to predict adverse events in Takotsubo syndrome patients.

Methods and Results—Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA$_2$DS$_2$-VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA$_2$DS$_2$-VASc score was 3 (interquartile range: 2–4). Overall, 9%, 42%, and 49% were included in Group A, B, and C, respectively. Follow-up length was 26±20 months. The mortality rate was 6%, 7%, and 17% in Group A, B, and C, respectively (P=0.011). The stroke rate was 3% and not different among the 3 groups. Estimated major adverse cardiac and cerebrovascular events (the composite of death, myocardial infarction, and stroke) rates in the 3 groups were 6%, 9%, and 17% in Group A, B, and C, respectively (P=0.033). The CHA$_2$DS$_2$-VASc score resulted as a predictor of major adverse cardiac and cerebrovascular events (odds ratio 2.1, 95% confidence interval, 1.2–3.6; P=0.01) and all-cause mortality (odds ratio 1.5, 95% confidence interval, 1.2–1.9; P=0.001).

Conclusions—In Takotsubo syndrome, the CHA$_2$DS$_2$-VASc score allows prediction of cardiovascular events and mortality at long-term follow-up. (J Am Heart Assoc. 2017;6:e006065. DOI: 10.1161/JAHA.117.006065.)

Key Words: anticoagulant • cardiovascular events • CHA$_2$DS$_2$-VASc score • stroke • Takotsubo • Takotsubo cardiomyopathy • Takotsubo syndrome

The validity of CHA$_2$DS$_2$-VASc score on stroke-risk stratification in patients with atrial fibrillation (AF) has been well documented and, although initially developed only for patients with AF, it has proved to be a helpful scoring system for evaluating the complexity of comorbidities in different clinical settings. The application of CHA$_2$DS$_2$-VASc score in patients without AF is relatively new and only a few non-AF studies have explored this simple method of risk assessment.

Goto et al demonstrated the potential of CHADS$_2$ score in predicting not only stroke but also cardiovascular death in stable outpatients at risk of atherothrombosis. Moreover, the CHADS$_2$ score has been reported to have a prognostic role in acute coronary syndrome patients without AF.

The Takotsubo syndrome (TTS) is an increasingly recognized cardiac condition that mimics an acute coronary syndrome and predominantly affects postmenopausal women. Several major cardiovascular and cerebrovascular events can complicate TTS, which should be considered as an acute heart failure syndrome with substantial morbidity and mortality. In particular, a stroke or transient ischemic attack rate of 1.7% per patient-year in a recent multicenter Registry was reported.

Oral anticoagulation is recommended in patients with TTS, if intraventricular thrombus is detected, but the role of prophylactic anticoagulation remains to be determined. A
CHADS2-VASc Score in Takotsubo

Parodi et al

Clinical Perspective

What Is New?

- This study demonstrated the ability of CHADS2-VASc score to predict a long-term composite end point of death, myocardial infarction, and stroke in Takotsubo patients.

What Are the Clinical Implications?

- CHADS2-VASc score could be considered an acceptable method for long-term risk stratification in Takotsubo patients, and likely in other patient populations without atrial fibrillation.

Methods

The design of this study was a multicenter, observational registry. Patients admitted to 20 centers participating in the Takotsubo Italian Network were included in the Registry according to the Takotsubo Italian Network diagnostic criteria11: (1) Typical transient left ventricular wall motion abnormalities extending beyond a single epicardial vascular distribution with complete functional normalization within 6 weeks; (2) Absence of potentially culprit coronary stenosis, or angiographic evidence of acute plaque rupture, dissection, thrombosis, or spasm; (3) New and dynamic ST-segment abnormalities or T-wave inversion or new-onset transient or permanent left bundle branch block; (4) Mild increase in myocardial injury markers (creatine kinase-MB value >50 U/L); (5) Clinical and/or instrumental exclusion of myocarditis; (6) Postmenopausal woman (optional); (7) Antecedent stressful event (optional). Antecedent stressful trigger event was defined as an occurrence that produced short-term physiological change that may lead directly to the onset of acute cardiovascular disease. They could be either emotional or physical (including acute medical or surgical emergencies).12 Coronary angiography was performed as soon as possible (ideally within 48 hours from admission).

The study was approved by the local Ethics Committees. All patients provided informed consent. The CHADS2-VASc score was calculated for each patient. Patients were divided into 3 groups according to the CHADS2-VASc score: Group A (≤1), B (2–3), and C (≥4). Patients were asked to return to our outpatient clinic for follow-up evaluation at 1 and 6 months, and annually thereafter. The primary end point was the composite of all-cause death, myocardial infarction, and stroke. Individual components of the primary end point as well as rehospitalization and AF were secondary end points.

Results

A total of 371 TTS patients were included in this observational registry (Table 1 summarizes baseline characteristics). The median CHADS2-VASc score was 3 (interquartile range: 2–4), ranging from 1 to 8. No patient showed a score of 0. Overall, 9%, 42%, and 49% subjects were included in Group A, B and C, respectively.

Patients with lower CHADS2-VASc score were more likely to have a trigger stressful event (91%, 79%, and 68% in Group A, B, C; P=0.007). They also had a lower rate of AF history (0%, 12%, 22%, P=0.002) and anticoagulant therapy at admission (0%, 8%, 14%, P=0.049). Of note, left ventricular ejection fraction at admission was significantly lower in Group C (0.37±0.10) compared with patients of Group A and B (0.41±0.10 and 0.40±0.10, P=0.007). During hospital stay, echographic evidence of left ventricular thrombosis was detected in 7 patients and none of them developed a clinical evidence of a cerebrovascular event. No significant difference in echographic evidence of left ventricular thrombosis was observed between the 3 study groups, at least in part influenced by the previous and in-hospital therapies and by the generally transitory and short-lived nature of the intra-ventricular thrombosis. The mean follow-up length was 26±20 months and the follow-up rate was 95%. The incidence of the primary end point as well as of all-cause
death was significantly higher in patients with high CHA2DS2-VASc scores than in patients with low CHA2DS2-VASc scores. All the other secondary end points did not significantly differ between groups (Table 2 summarizes the outcomes). During follow-up, 7 strokes occurred in this cohort of patients: 4 strokes were ischemic and attributed to AF-related embolism, 2 strokes were fatal events without additional diagnostic procedures, and 1 ischemic stroke occurred soon after surgical mitral valve repair. Estimated cumulative incidences of major adverse cardiac and cerebrovascular events in Group A, B, C are reported in Figure.

The CHA2DS2-VASc score was found to be a strong predictor of cardiovascular events (odds ratio 2.1, 95% confidence interval, 1.2–3.6; \(P=0.01\)) and mortality (odds ratio 1.5, 95% confidence interval, 1.2–1.9; \(P=0.001\), Table 3).

Discussion

TTS patients, being postmenopausal women with high hypertension and other comorbidity rates, are usually characterized by high CHA2DS2-VASc scores. This study demonstrated the ability of the CHA2DS2-VASc score to predict a composite end point of death, myocardial infarction, and stroke in TTS patients, suggesting its use as an acceptable method for long-term risk stratification in these patients. The CHA2DS2-VASc score has several desirable characteristics to be applied in TTS patients because it is easy to calculate and utilizes clinical data that are available at admission. Patients with CHA2DS2-VASc ≥4 showed a higher major adverse cardiac and cerebrovascular events rate, mainly driven by increased fatal events. Older age and a higher prevalence of comorbidities certainly contributed to the higher mortality rate in Group C.

### Table 1. Baseline Characteristics of Study Patients

| Variables                        | All (n=371) | Group A (n=33) | Group B (n=155) | Group C (n=183) |
|----------------------------------|-------------|----------------|----------------|-----------------|
| Age, y                           | 73±10       | 55±10*         | 70±8†          | 78±6*           |
| Female sex                       | 339 (91)    | 30 (91)        | 135 (87)†      | 174 (95)*       |
| Family history of CAD            | 58 (16)     | 0 (0)          | 12 (8)†        | 46 (25)†        |
| Smoker                           | 86 (23)     | 13 (39)†       | 37 (24)        | 36 (20)         |
| Hypertension                     | 236 (64)    | 1 (3)*         | 72 (46)†       | 163 (89)†       |
| Dyslipidemia                     | 123 (33)    | 8 (24)         | 50 (32)        | 65 (35)         |
| Diabetes mellitus                | 52 (14)     | 1 (3)†         | 7 (4)†         | 44 (24)†        |
| Congestive heart failure         | 3 (1)       | 0 (0)          | 0 (0)          | 3 (2)           |
| Peripheral vascular disease      | 38 (10)     | 0 (0)†         | 3 (2)†         | 35 (19)†        |
| Previous stroke/TIA              | 37 (10)     | 0 (0)†         | 1 (1)†         | 36 (20)†        |
| Trigger stressful event          | 275 (74)    | 30 (91)†       | 120 (79)       | 125 (68)†       |
| Variant type                     |             |                |                |                 |
| Apical                           | 245 (66)    | 28 (85)*       | 94 (61)†       | 123 (67)        |
| Midventricular                   | 127 (34)    | 13 (39)        | 55 (36)        | 59 (32)         |
| Basal                            | 16 (4)      | 1 (3)          | 7 (4)          | 8 (4)           |
| LVEF at admission                | 38±10       | 41±10†         | 40±10†         | 37±10†          |
| LVEF≤40%                         | 235 (63)    | 14 (45)†       | 94 (61)        | 127 (69)†       |
| LV thrombosis                    | 7 (2)       | 0 (0)          | 4 (3)          | 3 (2)           |
| Previous AF                      | 59 (16)     | 0 (0)†         | 19 (12)†       | 40 (22)†        |
| Oral anticoagulant at admission  | 37 (10)     | 0 (0)†         | 12 (8)         | 25 (14)†        |
| Discharge therapy                |             |                |                |                 |
| Aspirin                          | 278 (75)    | 26 (81)        | 112 (73)       | 139 (76)        |
| P2Y12 inhibitor                  | 129 (35)    | 12 (38)        | 48 (31)        | 68 (37)         |
| Dual antiplatelet agents         | 83 (22)     | 8 (24)         | 32 (21)        | 43 (23)         |
| Oral anticoagulant               | 46 (12)     | 0 (0)†         | 14 (9)         | 33 (18)†        |

AF indicates atrial fibrillation; CAD, coronary artery disease; LV, left ventricle; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack.

*\(P<0.05\) Group B; †\(P<0.05\) Group C; ‡\(P<0.05\) vs Group A.
patients as compared with Group A and B patients. On the contrary, nonfatal event rates (ie, myocardial infarction and ischemic stroke) were not significantly different between groups. It is unknown whether the more frequent use of anticoagulants in Group C has influenced this result.

Since myocardial dysfunction fully recovers in almost all of the patients within a few weeks, a substantial impact of Takotsubo-related left ventricular dysfunction on long-term outcomes seems unlikely. However, patients who had a TTS episode remain at risk for TTS recurrences and associated complications. On the other hand, it has been speculated that associated comorbidities could be relevant determinants of long-term prognosis of TTS.13

In our cohort of TTS subjects, with a low AF prevalence before and after the index event, the stroke rate at follow-up was lower than predicted by the CHA2DS2-VASc score, and not significantly different between groups, at least in part because of the low study power for this end point. However, no stroke occurred in TTS patients with CHA2DS2-VASc score ≤1.

TTS patients have a 10-fold higher risk of being affected by cerebrovascular accidents7 but the mechanisms underlying this association remain unclear. Probably, in the early phase, cardioembolism, because of the formation of intraventricular thrombus caused by transient but severe left ventricular systolic dysfunction, has a pivotal role. During hospitalization, daily monitoring of the left ventricular wall motion recovery by echocardiography is recommended to rule out apical thrombus in patients with persistent myocardial contraction abnormalities.14 However, the timing of thrombus formation and subsequent development of cardiogenic embolism has not been well documented. After the resolution of wall motion abnormalities and the recovery of systolic function, the formation of intraventricular thrombi is less likely. Indeed additional factors may play a role in the onset of cerebrovascular events. We should acknowledge that the variables included in the CHA2DS2-VASc score represent well-known cardiovascular risk factors (ie, age, hypertension, and diabetes mellitus) or manifestations of cardiovascular diseases (ie, heart failure, vascular disease, previous stroke/transient ischemic attack) able by themselves to impact patient long-term outcome. Therefore, TTS patients with high CHA2DS2-VASc score should not be considered at low risk for subsequent cardiovascular events. These patients should be carefully evaluated and a strict follow-up should be planned. Given the relevant event rates observed in patients with high CHA2DS2-VASc score, the intensification of secondary prevention strategies, including the selective use of antithrombotic agents (after careful bleeding risk assessment) seem justified in this subgroup of TTS patients.

Our results must be evaluated in light of some study limitations. First, this is a multicenter observational study and

---

**Table 2. Long-Term Outcome in the 3 Study Groups**

|                  | All (n=371) | Group A (n=33) | Group B (n=155) | Group C (n=183) | P Value* |
|------------------|-------------|---------------|----------------|----------------|----------|
| MACCE            | 48 (13)     | 2 (6)         | 14 (9)         | 32 (17)        | 0.033    |
| All-cause death  | 44 (12)     | 2 (6)         | 11 (7)         | 31 (17)        | 0.011    |
| MI               | 4 (1)       | 0 (0)         | 2 (1)          | 2 (1)          | 0.808    |
| Stroke           | 7 (2)       | 0 (0)         | 4 (3)          | 3 (2)          | 0.577    |
| Rehospitalization| 53 (14)     | 3 (9)         | 20 (13)        | 30 (16)        | 0.473    |
| Atrial fibrillation| 13 (3)     | 0 (0)         | 6 (4)          | 7 (4)          | 0.498    |

MACCE indicates major adverse cardiac and cerebrovascular events (all-cause death, myocardial infarction, stroke); MI, myocardial infarction.

*By log-rank test.

**Table 3. Predictors of MACCE and All-Cause Death**

|                  | MACCE HR | 95% CI          | P Value |
|------------------|----------|-----------------|---------|
| CHA2DS2-VASc score | 2.10     | 1.21 to 3.62    | 0.01    |
| Age, y           | 1.13     | 1.04 to 1.23    | 0.003   |
| All-cause death  | 1.51     | 1.20 to 1.93    | 0.01    |
| Age, y           | 1.11     | 1.06 to 1.16    | <0.001  |
| Diabetes mellitus| 2.86     | 1.29 to 6.35    | 0.01    |

CI indicates confidence interval; HR, hazard ratio; MACCE, major cardio-cerebrovascular events, the composite of death, infarction, and stroke.

---

**Figure.** Cumulative incidence curves depicting adverse event (MACCE; primary end point: the composite of death, infarction, and stroke) rates according to the CHA2DS2-VASc score: Group A, (≤1); Group B, (2–3); Group C, (≥4). MACCE indicates major adverse cardiac and cerebrovascular events.
the impact of clinical decision making based on risk stratification by CHA2DS2-VASc score in TTS patients is currently unknown. We also need to consider that no previous study evaluated the potential impact of pharmacological and preventive strategies on TTS long-term outcome, and the current management is largely empirical and variable among centers and attending physicians. Second, because of limited sample size, our study was probably not properly powered for rarely occurring events such as stroke. Finally, we cannot exclude the contribution of atherosclerotic coronary artery disease development to the higher long-term mortality rate of TTS with high CHA2DS2-VASc score as compared with the other groups. In fact, endothelial dysfunction, which constitutes the first step of atherosclerosis, has been suggested to be present in TTC,7–9 and several components of the score represent well-known coronary artery disease risk factors. However, coronary artery disease was demonstrated by baseline angiography in only a few patients and nonfatal myocardial infarction occurred in only 2 patients during follow-up.

Conclusions
The CHA2DS2-VASc score demonstrated significant discriminatory ability in predicting the incidence of major adverse cardiac and cerebrovascular events and the all-cause mortality at follow-up in our cohort of TTS patients. Further data are needed to identify the features of TTS patients with high risk of cardiovascular events, and to accurately select the most convenient antithrombotic treatment.

Appendix
Takotsubo Italian Network (TIN) Investigators
Corinna Armentano, MD, Ospedale Guglielmo da Saliceto, Piacenza, Italy; Costantino Astarita, MD, and Antonino Coppola, MD, Ospedale S. Maria della Misericordia, Sorrento, Naples, Italy; Amelia Ravera MD, Costantina Prota MD, and Pompea Bottiglieri, MD, Azienda Ospedaliera Universitaria “San Giovanni di Dio e Ruggi d’Aragona,” Salerno, Italy; Daniella Bovelli, MD, and Marco Mariano Patella, MD, Ospedale S. Maria, Terni, Italy; Marco Fabio Costantino, MD, Ospedale San Carlo, Potenza, Italy; Giovanni Gregorio, MD, and Michele Santoro, MD, Ospedale San Luca, Vallo della Lucania, Salerno, Italy; Fiore Manganelli, MD, and Francesco Rotondo, MD, Azienda Ospedaliera San Giuseppe Moscati, Avellino, Italy; Stefano Del Pace, MD, Careggi Hospital, Florence, Italy; Marco Pascotto, MD, Ospedale Fatebenefratelli, Naples, Italy; Elisabetta Grolla, MD, Ospedale Umberto I, Mestre, Venice, Italy; Ercole Tagliamonte, MD, Ospedale Umberto I, Nocera Inferiore, Salerno, Italy; Alfredo Bianchi, MD, Giovanni Marinoschi, MD, Michele Pappalettera, MD, and Andrea Pozzi MD, Ospedale di Circolo and Fondazione Macchi, Università dell’Insubria, Varese, Italy; Federico Nardi, MD, Ospedale Castelli, Verbania, Italy; Giuseppina Novo, MD, University of Palermo, Palermo, Italy; Francesco Antonini-Cantarini, MD, S. Maria degli Angeli Hospital, Pordenone, Italy; Francesco Bovenzi, MD, U.O. di Cardiologia, Ospedale Campo di Marte, Lucca.

Sources of Funding
This study was supported by A.R. CARD Foundation, Florence, Italy.

Disclosures
Dr Parodi reported receiving consulting or lecture fees from AstraZeneca, Bayer, Chiesi, Daiichi Sankyo/Eli Lilly, and Merck. Di Mario received research grants from Abbott and Medtronic. The remaining authors have no disclosures to report.

References
1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2664–2670.
2. Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011;42:1768–1770.
3. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100:1524–1530.
4. Poci D, Hartford M, Karlsson T, Herlitz J, Edvardsson N, Caidsahl K. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest. 2012;141:1434–1440.
5. Morillas P, Pallares V, Facila L, Listeri JL, Sebastian ME, Gomez M, Castella E, Camarasa R, Sandin M, Garcia-Honrubia A. The CHADS2 score to predict stroke risk in the absence of atrial fibrillation in hypertensive patients aged 65 years or older. Rev Esp Cardiol. 2015;68:485–491.
6. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D’Agostino R, Ohman EM, Liu CS, Hirsch AT, Mas JL, Wilson PW, Corbalan R, Aichner F, Steg PG. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855–863.
7. Pelliccia F, Parodi G, Greco C, Antonucci D, Brenner R, Bossone E, Cacciotti L, Capucci A, Citro R, Delmas C, Guerra F, Ionescu CN, Lairez D, Larrauri-Reyes M, Lee PH, Mansencal N, Marazzi G, Mihos CG, Morel O, Nef HM, Nunez Gil JJ, Passaseo I, Pineda AM, Rosano G, Santana O, Schneck F, Song BG, Song JK, Teh AW, Ungprasert P, Valbusa A, Wahl A, Yoshida T, Gaudio C, Kaski JC. Comorbidities frequency in Takotsubo syndrome: an international collaborative systematic review including 1109 patients. Am J Med. 2015;128:654.e11–654.e19.
8. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18:8–27.
9. Parodi G, Del S, Carrabba N, Salvadori C, Memisha G, Simonetti I, Antonucci D, Gensini GF. Incidence, clinical findings and outcome of
women with left ventricular apical ballooning syndrome. Am J Cardiol. 2007; 99:182–185.

10. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jennewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschoppe C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koening W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Oswald S, Galliuto L, Crea F, Dichtl W, Franz WM, Enpen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–938.

11. Parodi G, Citro R, Bellandi B, Provenza G, Marrani M, Bossone E. Revised clinical diagnostic criteria for Tako-tsubo syndrome: the Tako-tsubo Italian Network proposal. Int J Cardiol. 2014;172:282–283.

12. Del Pace S, Parodi G, Bellandi B, Zampini L, Venditti F, Ardito M, Antoniucci D, Gensini GF. Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study. Clin Res Cardiol. 2011;100:523–529.

13. Parodi G, Bellandi B, Del Pace S, Barchielli A, Zampini L, Velluzzi S, Carrabba N, Gensini GF, Antoniucci D. Natural history of tako-tsubo cardiomyopathy. Chest. 2011;139:887–892.

14. Citro R, Lyon AR, Meimoun P, Omerovic E, Redfors B, Buck T, Lerakis S, Parodi G, Silverio A, Eitel I, Schneider B, Prasad A, Bossone E. Standard and advanced echocardiography in Takotsubo (stress) cardiomyopathy: clinical and prognostic implications. J Am Soc Echocardiogr. 2015;28:57–74.
Risk Stratification Using the CHA²DS₂–VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network
Guido Parodi, Fernando Scudiero, Rodolfo Citro, Angelo Silverio, Benedetta Bellandi, Concetta Zito, Francesco Antonini-Canterin, Fausto Rigo, Chiara Zocchi, Eduardo Bossone, Jorge Salerno-Uriarte, Federico Piscione, Carlo Di Mario and Takotsubo Italian Network (TIN)

J Am Heart Assoc. 2017;6:e006065; originally published September 14, 2017;
doi: 10.1161/JAHA.117.006065
The Journal of the American Heart Association is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/6/9/e006065

Subscriptions, Permissions, and Reprints: The Journal of the American Heart Association is an online only Open Access publication. Visit the Journal at http://jaha.ahajournals.org for more information.